Review
Biochemistry & Molecular Biology
Mihaela Raluca Radu, Alina Pradatu, Florentina Duica, Romeo Micu, Sanda Maria Cretoiu, Nicolae Suciu, Dragos Cretoiu, Valentin Nicolae Varlas, Viorica Elena Radoi
Summary: Ovarian cancer is a common cause of death in women, with early diagnosis being crucial. Genomic instability is a hallmark of the cancer, and there is diversity within different subtypes. Early detection leads to a favorable prognosis.
Review
Oncology
Rossella Reddavid, Simona Dagatti, Caterina Franco, Lucia Puca, Mariano Tomatis, Simona Corso, Silvia Giordano, Maurizio Degiuli
Summary: Despite the addition of molecular therapy in the clinical treatment of advanced and metastatic gastric cancer, the survival benefits of these novel therapies remain rather unclear, possibly due to inaccurate patient selection.
Article
Multidisciplinary Sciences
Zixiang Wang, Shourong Wang, Junchao Qin, Xiyu Zhang, Gang Lu, Hongbin Liu, Haiyang Guo, Ligang Wu, Victoria O. Shender, Changshun Shao, Beihua Kong, Zhaojian Liu
Summary: This study reveals that altered expression of splicing factor BUD31 can enhance ovarian cancer progression by promoting exon inclusion in the anti-apoptotic BCL2 family member, BCL2L12. The findings highlight the critical role of BUD31-regulated exon inclusion in ovarian cancer cell survival and cancer progression.
NATURE COMMUNICATIONS
(2022)
Review
Medicine, General & Internal
Laura M. Harbin, Holly H. Gallion, Derek B. Allison, Jill M. Kolesar
Summary: Ovarian cancer is a deadly gynecologic malignancy, and precision medicine and molecular biomarker testing can help improve treatment outcomes.
Article
Oncology
Shannon N. Westin, Marilyne Labrie, Jennifer K. Litton, Aurora Blucher, Yong Fang, Christopher P. Vellano, Joseph R. Marszalek, Ningping Feng, XiaoYan Ma, Allison Creason, Bryan Fellman, Ying Yuan, Sanghoon Lee, Tae-Beom Kim, Jinsong Liu, Anca Chelariu-Raicu, Tsun Hsuan Chen, Nashwa Kabil, Pamela T. Soliman, Michael Frumovitz, Katheleen M. Schmeler, Amir Jazaeri, Karen H. Lu, Rashmi Murthy, Larissa A. Meyer, Charlotte C. Sun, Anil K. Sood, Robert L. Coleman, Gordon B. Mills
Summary: This study aimed to confirm the recommended phase II dose for the combination of olaparib and capivasertib in multiple cancers, and evaluate molecular markers of response and resistance. Promising responses, especially in endometrial cancer, were observed among the 38 enrolled patients. Therapy resistance was associated with specific signaling pathways and metabolic factors.
CLINICAL CANCER RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Susana Hernando Polo, Diana Moreno Munoz, Adriana Carolina Rosero Rodriguez, Jorge Silva Ruiz, Diana Isabel Rosero Rodriguez, Felipe Counago
Summary: For metastatic castration-resistant prostate cancer, novel targeted therapies are changing the treatment landscape, with PARPi inhibitors showing significant benefits but being ineffective for resistant tumors and wildtype BRCA tumors.
Review
Reproductive Biology
Shona Nag, Shyam Aggarwal, Amit Rauthan, Narayanankutty Warrier
Summary: Epithelial ovarian cancer is a highly lethal gynecological cancer, often diagnosed at an advanced stage. Cytoreductive surgery along with chemotherapy is the main treatment approach. In recent years, neo-adjuvant chemotherapy followed by interval surgery and maintenance therapy have gained importance. PARP inhibitors have shown promising results as maintenance therapy, especially for tumors with homologous recombination deficiency.
JOURNAL OF OVARIAN RESEARCH
(2022)
Review
Oncology
M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata
Summary: Personalized medicine has revolutionized the management of advanced ovarian cancer, with biomarker-driven clinical trials leading to practice-changing results such as the use of poly-ADP ribose polymerase inhibitors in maintenance therapy for patients with homologous recombination defects. Recent therapeutic breakthroughs have mainly focused on high grade serous carcinoma, while advancements in less common histotypes remain limited.
CANCER TREATMENT REVIEWS
(2021)
Review
Oncology
Jiahua Liu, Junnan Ma, Jiarong Zhang, Chengming Li, Bowen Yu, Hyok Chol Choe, Kaiyue Ding, Liu Zhang, Lin Zhang
Summary: This article uses bibliometric software to analyze articles on ovarian cancer and drug resistance, providing new ideas and directions for researchers in this field. The research shows an increasing trend from 2013 to 2022, with more contributions from China and Chinese institutions. The research hotspots in this field mainly focus on the in-depth exploration of the drug resistance mechanism of ovarian cancer and the progress of PARP inhibitors and bevacizumab in the treatment of ovarian cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Obstetrics & Gynecology
Q. Lin, W. Liu, S. Xu, H. Shang, J. Li, Y. Guo, J. Tong
Summary: The study found that PARP inhibitors are effective as maintenance therapy for patients with newly diagnosed advanced ovarian cancer, providing significant progression-free survival benefits regardless of BRCA mutation or homologous recombination deficiency status. This new treatment approach is crucial in preventing relapse in up to 70% of patients after primary therapy.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Nicholas McNamee, Ines Pires da Silva, Adnan Nagrial, Bo Gao
Summary: Small-cell lung cancer (SCLC) is an aggressive disease with limited treatment options and poor survival rates. While there have been significant advancements in the treatment of non-small cell lung cancer (NSCLC), SCLC has not seen the same level of progress. This is due, in part, to the complex and heterogeneous nature of SCLC tumors. This review explores the current treatment paradigm of SCLC, recent advances in immunotherapy, challenges in identifying predictive biomarkers, and potential future directions in SCLC treatment research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso
Summary: Ovarian cancer treatment relies on cytoreductive surgery, platinum-based chemotherapy, and targeted therapies. While PARP inhibitors have shown remarkable results, immunotherapy outcomes have been disappointing. Further research on combining different treatment modalities is warranted.
Review
Oncology
Fergus Keane, Catherine A. O'Connor, Wungki Park, Thomas Seufferlein, Eileen M. O'Reilly
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death in the US. PDAC with gBRCA1/2 mutations has a more favorable prognosis and additional treatment options compared to an unselected PDAC cohort. Efforts are being made to expand the use of PARP inhibitors to other genetic mutations associated with deficient DNA damage repair (DDR). Resistance to platinum-based chemotherapies and PARPi remains a challenge in improving long-term outcomes.
Review
Pharmacology & Pharmacy
Chuanlin Wang, Pengning Gao, Jiali Xu, Shanling Liu, Wenda Tian, Jiayu Liu, Lan Zhou
Summary: This article reviews the role of natural phytochemicals in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors, and finds that these substances have significant alleviating effects on atherosclerosis, nausea, and vomiting.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Immunology
Hongyu Xie, Wenjie Wang, Wencai Qi, Weilin Jin, Bairong Xia
Summary: Combining DDR inhibitors with ICI therapy in ovarian cancer can enhance local antigen release, promote systemic antitumor immune responses, and potentially improve clinical outcomes for patients with ovarian cancer. This combination therapy strategy is based on the interconnectivity between DDR pathway deficiency and immune response, and it is supported by available clinical trials and potential predictive biomarkers.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)
